Maria Chaudhry, MBBS

home / authors / maria-chaudhry-mbbs

Articles

Dr. Chaudhry on Novel Treatment Regimens in Relapsed/Refractory Multiple Myeloma

Dr. Chaudhry on Novel Treatment Regimens in Relapsed/Refractory Multiple Myeloma

Maria Chaudhry, MBBS
January 16th 2020

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses novel treatment regimens in relapsed/refractory multiple myeloma.

Read More

Dr. Chaudhry on Unmet Needs in Relapsed/Refractory Multiple Myeloma

Dr. Chaudhry on Unmet Needs in Relapsed/Refractory Multiple Myeloma

Maria Chaudhry, MBBS
January 9th 2020

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.

Read More

Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

Maria Chaudhry, MBBS
January 7th 2020

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data